Latest / The Line Podcast / On The Line: How and why Canadian health care fell years behind
Transcript
- 0:00SPEAKER_00: Where the hell am I?
- 0:01SPEAKER_00: Some of you might have noticed I am using a virtual background.
- 0:05SPEAKER_00: I'm in a hotel room because I'm actually on the road to record this interview
- 0:08SPEAKER_00: and kick off a couple of other meetings as well.
- 0:11SPEAKER_00: I am at BioCanRx headquarters in Ottawa to talk about why Canada is falling behind
- 0:17SPEAKER_00: in healthcare,
- 0:18SPEAKER_00: why we spend so much money to have a lot of what we're actually producing leave
- 0:22SPEAKER_00: the country,
- 0:23SPEAKER_00: usually to the United States,
- 0:25SPEAKER_00: and why you may one day We're going to talk about that in moments.
- 0:30SPEAKER_00: This is On The Line.
- 0:35[music]
- 0:53SPEAKER_00: Before we get into this episode, guys, I want to make a personal and business disclosure here.
- 0:59SPEAKER_00: BioCanRx has been and continues to be a sponsor of The Line.
- 1:04SPEAKER_00: My next interview, we're about to hear, is with Stephanie Michaud.
- 1:08SPEAKER_00: The President and CEO of Biocan Rx.
- 1:11SPEAKER_00: I'm going to tell you in a minute the personal connection that made this happen,
- 1:14SPEAKER_00: but for business reasons, let me just disclose that up front.
- 1:17SPEAKER_00: They are a commercial partner.
- 1:19SPEAKER_00: This is not advertorial, though.
- 1:21SPEAKER_00: They did not pay for this time.
- 1:23SPEAKER_00: They had no control over the questions.
- 1:25SPEAKER_00: They had no editorial guidance for the interview.
- 1:27SPEAKER_00: They did not know in advance what I would be asking.
- 1:30SPEAKER_00: The only edits that we made to this podcast are to cover up me choking on my water
- 1:34SPEAKER_00: and And a doorbell ringing.
- 1:37SPEAKER_00: So it's presented to you as the conversation happened.
- 1:40SPEAKER_00: This has happened before.
- 1:41SPEAKER_00: It's happened.
- 1:42SPEAKER_00: I mean, hey, hopefully it'll happen again because I hope we continue to get many sponsors.
- 1:46SPEAKER_00: I did want to make that very clear up front, though.
- 1:48SPEAKER_00: That is...
- 1:50SPEAKER_00: Disclosure, you guys should know.
- 1:52SPEAKER_00: It did not influence the questions I wanted to ask,
- 1:54SPEAKER_00: but we should be honest with our audience up front to maintain trust,
- 1:58SPEAKER_00: so consider that disclosure on the record.
- 2:00SPEAKER_00: I want to make a personal disclosure as well before we get into this episode,
- 2:04SPEAKER_00: and regular listeners or readers of mine will know that about a year ago,
- 2:08SPEAKER_00: my family was hit out of the blue with a devastating cancer diagnosis.
- 2:12SPEAKER_00: My wife,
- 2:13SPEAKER_00: who was young and as far as we knew healthy,
- 2:16SPEAKER_00: Was one of the many Canadians who was bluntly failed by the healthcare system
- 2:20SPEAKER_00: and something that should have been caught wasn't.
- 2:23SPEAKER_00: The initial diagnosis was so bad that I thought she was going to die
- 2:29SPEAKER_00: and I didn't think it was going to take that long.
- 2:32SPEAKER_00: We've had a good course of treatment since the situation is much better now.
- 2:38SPEAKER_00: At the very least,
- 2:38SPEAKER_00: we've bought ourselves a lot of time and with that time,
- 2:41SPEAKER_00: we might be able to do something even better.
- 2:44SPEAKER_00: When my wife was diagnosed,
- 2:46SPEAKER_00: one of my first calls was to my old friend, Ken, one of my closest friends.
- 2:50SPEAKER_00: Ken works for BioCanRx,
- 2:53SPEAKER_00: and it was just a very weird small world coincidence that
- 2:57SPEAKER_00: as I suddenly found myself needing to learn everything I could about cancer,
- 3:02SPEAKER_00: one of my closest friends worked for a Canadian nonprofit at the forefront
- 3:06SPEAKER_00: of cancer therapies in this country.
- 3:09SPEAKER_00: I shamelessly took advantage of his connections and spoke with his colleagues
- 3:14SPEAKER_00: and staff to learn as much as I could,
- 3:16SPEAKER_00: because frankly, I had to, given the situation.
- 3:19SPEAKER_00: And as I did that,
- 3:20SPEAKER_00: I began to realize there were a lot of questions that were of immediate interest
- 3:24SPEAKER_00: to me and my family, but that the broader public should have known as well.
- 3:28SPEAKER_00: This interview...
- 3:30SPEAKER_00: It was set in motion before we ever inked a sponsorship deal with BioCanRx.
- 3:34SPEAKER_00: It just took a while to organize the logistics.
- 3:37SPEAKER_00: As you can imagine, on the home front, I've been busy.
- 3:40SPEAKER_00: So a professional disclosure on behalf of The Line, a personal disclosure on my own behalf.
- 3:47SPEAKER_00: Listen now to my interview with Stephanie Michaud,
- 3:50SPEAKER_00: the President and CEO of BioCanRx,
- 3:52SPEAKER_00: as she explains to me,
- 3:54SPEAKER_00: How our healthcare system works,
- 3:55SPEAKER_00: how new technologies in this country are funded and then developed and
- 3:59SPEAKER_00: then maybe even deployed,
- 4:01SPEAKER_00: and why one day your life may depend on a Canadian invention that isn't available
- 4:07SPEAKER_00: in Canada.
- 4:11SPEAKER_00: Stephanie Michaud, President, CEO, BiocanRx.
- 4:14SPEAKER_00: I'm here at your facility in Ottawa, which I didn't realize was in a hospital.
- 4:19SPEAKER_00: With hindsight, that actually does make a lot of sense.
- 4:22SPEAKER_00: Like, I don't know where I expected it to be, but I guess a hospital checks out.
- 4:26SPEAKER_00: So one of the things I've already confessed to you,
- 4:29SPEAKER_00: and I confess this to you even before we started recording...
- 4:32SPEAKER_00: The stuff that you are an expert in is at the outer limits of my knowledge.
- 4:37SPEAKER_00: So I'm here and I've been trying to understand a lot of this stuff
- 4:41SPEAKER_00: for my own family reasons for the last 10 months.
- 4:44SPEAKER_00: But I want to start with a big picture question.
- 4:46SPEAKER_00: And then I think we'll get a little more granular as we go.
- 4:50SPEAKER_00: When my family became just like other thousands
- 4:53SPEAKER_00: of other Canadian families every year,
- 4:54SPEAKER_00: just when a doctor walked into a room and said, cancer.
- 4:58SPEAKER_00: I had to start living in a system that I had only understood in the abstract.
- 5:03SPEAKER_00: And one of the things I immediately figured out,
- 5:05SPEAKER_00: and it cuts both ways,
- 5:07SPEAKER_00: is that Canadian healthcare in general is actually really good at oncology,
- 5:12SPEAKER_00: that we do an excellent job treating cancers.
- 5:16SPEAKER_00: But one of the things I also realized very quickly is that we are anywhere,
- 5:20SPEAKER_00: and it depends exactly on what,
- 5:22SPEAKER_00: but three, five,
- 5:23SPEAKER_00: maybe 10 years behind the state of the art compared to some of our peer countries.
- 5:28SPEAKER_00: That might not matter if you have,
- 5:30SPEAKER_00: and I hate to use the term, a fairly routine, treatable cancer.
- 5:35SPEAKER_00: If you're right on the frontier of what's possible,
- 5:38SPEAKER_00: if you're three years behind the state of the art,
- 5:40SPEAKER_00: that can mean the difference between life and death.
- 5:43SPEAKER_00: Where does,
- 5:44SPEAKER_00: and we'll get into the specifics of what your organization does,
- 5:46SPEAKER_00: but where does Canada fit internationally in treating cancers,
- 5:50SPEAKER_00: and even more broadly, other advanced and complicated diseases?
- 5:54SPEAKER_01: Thank you for the question.
- 5:56SPEAKER_01: And I thank you for sharing the story of your family.
- 6:00SPEAKER_01: It's really important.
- 6:02SPEAKER_01: And I'm sorry that you've Had to learn so much about this disease.
- 6:07SPEAKER_01: That's hugely, challenging.
- 6:08SPEAKER_00: I wouldn't recommend
- 6:09SPEAKER_01: it.
- 6:10SPEAKER_01: No, I know about this disease as well, unfortunately.
- 6:14SPEAKER_01: Canada, as you've noted, does really quite well with respect to cancer treatments.
- 6:20SPEAKER_01: So we have a good intake process.
- 6:23SPEAKER_01: Individuals, we have differences in how care is delivered across the country.
- 6:30SPEAKER_01: With respect to screening,
- 6:31SPEAKER_01: but we are typically able to catch most people as their cancers develop
- 6:38SPEAKER_01: through different screening programs or actually having
- 6:42SPEAKER_01: The universal healthcare approach that we have.
- 6:46SPEAKER_01: But you're absolutely right when it comes to innovative drugs,
- 6:50SPEAKER_01: new treatments that we see are being offered in other jurisdictions like the US,
- 6:56SPEAKER_01: for example.
- 6:57SPEAKER_01: And of course, we hear a lot about it because we're right next door to them.
- 7:01SPEAKER_01: We're behind.
- 7:02SPEAKER_01: We have a different system when it comes to evaluating a drug,
- 7:06SPEAKER_01: when it comes to reimbursement of a drug, and those things take time.
- 7:12SPEAKER_01: And given the universal nature of our healthcare system,
- 7:16SPEAKER_01: decisions are made about cost,
- 7:19SPEAKER_01: decisions are made about whether there's value,
- 7:23SPEAKER_01: and sometimes products that are offered elsewhere don't make it here.
- 7:28SPEAKER_00: I know at BioCanorex,
- 7:30SPEAKER_00: you guys are focused on immunotherapies,
- 7:32SPEAKER_00: which is like a subset of the broader pharmaceutical side of this.
- 7:36SPEAKER_00: But one of the things I ran into early in the process,
- 7:39SPEAKER_00: and it was very much on the equipment side,
- 7:41SPEAKER_00: which I think is probably a different regulatory environment,
- 7:43SPEAKER_00: but I think the same problem.
- 7:45SPEAKER_00: Which was that some of the doctors who were involved in my family's care were going,
- 7:50SPEAKER_00: I really,
- 7:50SPEAKER_00: really wish we could get this damned machine that they're already using in
- 7:54SPEAKER_00: the United States.
- 7:55SPEAKER_00: And I was just in Chicago for a conference and all the American doctors were talking
- 7:59SPEAKER_00: about how this has just been a step change and how they are treating like
- 8:02SPEAKER_00: the exact kind of cancer that I was worried about.
- 8:06SPEAKER_00: And I just kind of said, well, like, this is just me.
- 8:08SPEAKER_00: Like I said, I'm at the limits of my knowledge here.
- 8:10SPEAKER_00: And I said, well, why don't we use them in Canada?
- 8:12SPEAKER_00: And they're like, oh,
- 8:13SPEAKER_00: I'm sure we will after five years of data is gathered and then assessed in a process
- 8:21SPEAKER_00: that will take between one to three years.
- 8:23SPEAKER_00: So this thing that is already in use in the United States,
- 8:26SPEAKER_00: saving patients who would have been written off as palliative a year or two ago.
- 8:31SPEAKER_00: Canadians,
- 8:33SPEAKER_00: unless they have the money to go buy it in the United States
- 8:36SPEAKER_00: or just get direct access, five to eight year delay.
- 8:41SPEAKER_00: And that's just the system we've designed because we won't even consider looking
- 8:44SPEAKER_00: at it until we have data that shows that it is a financial improvement
- 8:48SPEAKER_00: over what we're already using.
- 8:50SPEAKER_01: Absolutely.
- 8:51SPEAKER_00: And five years of data is required to make that argument.
- 8:54SPEAKER_00: Now,
- 8:54SPEAKER_00: I do understand that sometimes extraordinary breakthroughs can get fast tracked,
- 8:58SPEAKER_00: but in general,
- 8:59SPEAKER_00: We're really good at treating the regular stuff,
- 9:01SPEAKER_00: but we're not even trying to be on the frontier.
- 9:04SPEAKER_01: Yes.
- 9:05SPEAKER_01: I have no other answer than yes.
- 9:11SPEAKER_01: And of course, it becomes really apparent because we live right next door to the US.
- 9:17SPEAKER_01: And that collection of data,
- 9:20SPEAKER_01: waiting for the amount of time to do the proper evaluation,
- 9:23SPEAKER_01: We have a different system.
- 9:25SPEAKER_01: And so when a new device is approved in the United States, what happens?
- 9:31SPEAKER_01: It's what the market will bear, right?
- 9:33SPEAKER_01: And there isn't that secondary evaluation of value for money.
- 9:38SPEAKER_01: There is that secondary evaluation of value for money in Canada.
- 9:43SPEAKER_01: And this is how the resources that we have that are allocated to healthcare are allocated.
- 9:49SPEAKER_01: It's complex and there are many different checks and balances,
- 9:54SPEAKER_01: but yes, ultimately things happen later.
- 9:59SPEAKER_01: Things take longer because in the United States it's market-driven forces.
- 10:05SPEAKER_00: We'll move on from this in a minute,
- 10:06SPEAKER_00: but there was another variant of that story,
- 10:09SPEAKER_00: which I heard in a,
- 10:10SPEAKER_00: in a very Canadian fashion in a hockey dressing room from one of the other guys
- 10:14SPEAKER_00: who is a surgeon at an odd hospital in Toronto.
- 10:17SPEAKER_00: And he was just griping about the fact that he'd been,
- 10:19SPEAKER_00: again, At a conference in the United States and all the doctors there.
- 10:23SPEAKER_00: And it wasn't even a tool that was used in procedures.
- 10:27SPEAKER_00: It was a cleaning and sterilization tool that was just better and faster and allowed
- 10:32SPEAKER_00: the office and the procedures to be done quicker and
- 10:35SPEAKER_00: the back end was more organized.
- 10:37SPEAKER_00: And he went up to the company that was making them and he's like,
- 10:39SPEAKER_00: I would love to get one of these.
- 10:40SPEAKER_00: And they're like, oh, cool.
- 10:41SPEAKER_00: What hospital are you at?
- 10:42SPEAKER_00: He's like, well, I'm at a hospital in Toronto.
- 10:44SPEAKER_00: And he says they just immediately lost interest in him because they have tried
- 10:47SPEAKER_00: and failed to sell into the Canadian system before.
- 10:49SPEAKER_00: They're like, oh, yeah, yeah.
- 10:50SPEAKER_00: Okay.
- 10:50SPEAKER_00: Here's our card.
- 10:51SPEAKER_00: Here's a brochure.
- 10:52SPEAKER_00: If he'd been coming from a hospital in Boston or Minneapolis,
- 10:55SPEAKER_00: they would have wanted to sell it to him because he would have had the budget
- 10:58SPEAKER_00: to go out and say, I will buy this.
- 11:00SPEAKER_00: Trying to go do it through the Ontario system.
- 11:01SPEAKER_00: He said they handed him a brochure,
- 11:04SPEAKER_00: rolled their eyes, and then went to go talk to a customer who might actually buy.
- 11:08SPEAKER_01: This is exactly what you've stated.
- 11:12SPEAKER_01: Difficulties in terms of being able to sell directly to a hospital is something
- 11:17SPEAKER_01: that we hear all of the time, especially in the area of medical devices.
- 11:24SPEAKER_01: Different provinces are trying different approaches with respect to procurement,
- 11:28SPEAKER_01: especially because we do have a lot of medical device manufacturers here in Canada
- 11:32SPEAKER_01: that have outstanding products,
- 11:34SPEAKER_01: that have the data,
- 11:35SPEAKER_01: that have been able to sell in the US and in other jurisdictions.
- 11:39SPEAKER_01: They've got this great data.
- 11:41SPEAKER_01: However,
- 11:42SPEAKER_01: that whole pathway of navigating procurement,
- 11:46SPEAKER_01: even after you have approval in Canada, is...
- 11:51SPEAKER_01: Difficult.
- 11:51SPEAKER_01: It's very arduous.
- 11:53SPEAKER_01: And decisions are made in a different way, right?
- 11:57SPEAKER_01: The way that these budgets are managed.
- 11:59SPEAKER_01: And this has been highlighted to the federal government and provincial governments
- 12:03SPEAKER_01: about this siloing.
- 12:05SPEAKER_01: And really, you're not buying for innovation is something that they get told all of the time.
- 12:12SPEAKER_01: I think that message has made it, has come across and has come through and changes our foot.
- 12:18SPEAKER_01: Certainly there are different types of pilot programs
- 12:21SPEAKER_01: that are being tried specifically for medical devices in Ontario.
- 12:26SPEAKER_01: It'll be very interesting to see where that ends up and whether
- 12:29SPEAKER_01: or not we're actually able to see,
- 12:30SPEAKER_01: right, these innovative products that change the game and make us more efficient.
- 12:35SPEAKER_01: You know, you would think that makes sense.
- 12:37SPEAKER_01: It's really practical, right?
- 12:40SPEAKER_01: But yeah, we have old systems.
- 12:43SPEAKER_00: So we've been talking about devices,
- 12:44SPEAKER_00: and I confess we've been talking about devices because that's what I know more
- 12:47SPEAKER_00: about.
- 12:48SPEAKER_00: What you guys do are not devices.
- 12:50SPEAKER_00: What is your regulatory environment like?
- 12:53SPEAKER_00: And I want to talk about the commercialization difficulties because I know that's
- 12:58SPEAKER_00: a big part of the problem that we run and do here.
- 13:00SPEAKER_00: But when you or one of the researchers you work with has an aha moment and has
- 13:07SPEAKER_00: a breakthrough and does something scientifically that could be a game changer,
- 13:11SPEAKER_00: we're like, wow, we've solved a riddle, right?
- 13:13SPEAKER_00: We've actually cracked some of this.
- 13:16SPEAKER_00: What the hell happens next?
- 13:18SPEAKER_00: Like, how do you actually start going from scientists with smart idea?
- 13:23SPEAKER_00: How do you in Canada get that turned into an actual therapy that could save a life?
- 13:28SPEAKER_01: That could save a life.
- 13:29SPEAKER_01: It's a fantastic question and it's the reason why we exist.
- 13:35SPEAKER_01: This has traditionally been an underfunded,
- 13:38SPEAKER_01: underinvested area of research in Canada,
- 13:41SPEAKER_01: specifically with respect to drug development.
- 13:43SPEAKER_01: So the first thing to do is to Surprise, surprise.
- 13:47SPEAKER_01: Validate the result, right?
- 13:49SPEAKER_01: And execute a proof of concept.
- 13:51SPEAKER_01: Once you obtain a positive result from that,
- 13:54SPEAKER_01: then the next step is to make the decision,
- 13:57SPEAKER_01: okay, do we want to try this in a clinical trial?
- 14:00SPEAKER_01: And to start thinking about what the manufacturing of this product is going to look like.
- 14:06SPEAKER_01: For us, most of the products that we work with are biologics.
- 14:12SPEAKER_01: So...
- 14:14SPEAKER_01: It's not a small molecule.
- 14:15SPEAKER_01: It comes from a living system.
- 14:17SPEAKER_01: It can be a very large protein like an antibody.
- 14:20SPEAKER_01: It can be a virus.
- 14:22SPEAKER_01: It can be a cell.
- 14:23SPEAKER_01: It can be a genetically modified cell.
- 14:26SPEAKER_01: And I hope what you're getting through this,
- 14:29SPEAKER_01: it's really expensive, really, really expensive to make.
- 14:35SPEAKER_01: And so the next stage that needs to happen is, yes, we make the decision.
- 14:39SPEAKER_01: We do want to go to a trial.
- 14:42SPEAKER_01: How are we going to make this?
- 14:44SPEAKER_01: And what is the process to make this?
- 14:46SPEAKER_01: And then it's filling out The paperwork that will enable us to go knock
- 14:51SPEAKER_01: on Health Canada's door to say,
- 14:54SPEAKER_01: we have an exciting new product and this is how we think it should be evaluated
- 14:58SPEAKER_01: in humans.
- 15:01SPEAKER_01: In our case,
- 15:02SPEAKER_01: to address cancers in a certain indication because we believe that this is
- 15:08SPEAKER_01: the mechanism of action and go from there.
- 15:11SPEAKER_01: And that is a huge gap in Canada,
- 15:14SPEAKER_01: but those are the steps that are necessary to get that product first into people.
- 15:18SPEAKER_00: I'm probably going to get myself in trouble here.
- 15:21SPEAKER_00: You have complete permission to correct me if I'm wrong about this,
- 15:24SPEAKER_00: but my understanding is cancer treatment traditionally had been using chemotherapy,
- 15:30SPEAKER_00: basically not to put too fine a point on this,
- 15:33SPEAKER_00: but poison that will kill the cancer slightly faster than it will kill the patient
- 15:38SPEAKER_00: or other sort of direct treatments like radiation.
- 15:40SPEAKER_00: Again, that will destroy a cancer in a place or surgery, which is what we should.
- 15:45SPEAKER_00: Okay.
- 15:45SPEAKER_00: It's contained.
- 15:46SPEAKER_00: It's isolated.
- 15:47SPEAKER_00: We will surgically remove it.
- 15:49SPEAKER_00: And when you were talking about viruses and molecules and things like that,
- 15:53SPEAKER_00: immunotherapies are basically finding a way to either train the immune system
- 15:58SPEAKER_00: to go out and find cancer that is invisible to it,
- 16:01SPEAKER_00: or is to turn off cancer's ability significantly.
- 16:03SPEAKER_00: I
- 16:09SPEAKER_00: can only imagine the cost and the time to generate these viruses and molecules.
- 16:16SPEAKER_00: I'm having terrifying flashbacks to grade 11 science here.
- 16:19SPEAKER_00: That's where I stopped, which is why I'm into trouble when I talk too much about this.
- 16:24SPEAKER_00: When...
- 16:26SPEAKER_00: I could be wrong about this,
- 16:27SPEAKER_00: but my understanding is the research is relatively well funded in Canada,
- 16:31SPEAKER_00: where if you are a scientist out there who wants to find that virus
- 16:34SPEAKER_00: or actually genetically engineer something or build that molecule,
- 16:38SPEAKER_00: there will be money to do that.
- 16:40SPEAKER_00: Am I correct about that?
- 16:41SPEAKER_00: Like for the actual basic research part?
- 16:43SPEAKER_01: So you're going to get me into trouble now.
- 16:45SPEAKER_01: Okay.
- 16:46SPEAKER_01: I didn't mean to.
- 16:47SPEAKER_01: No, no, no.
- 16:48SPEAKER_01: It's relative to the area of research that we invest in, which is called translational research.
- 16:57SPEAKER_01: It's well-funded relative to us.
- 17:01SPEAKER_01: That being said, the success rates at the federal funder CIHR, it's fallen below 13%.
- 17:08SPEAKER_01: So there's a lot of pressure on the system for research.
- 17:14SPEAKER_01: And Canada typically has under-invested in research overall relative
- 17:20SPEAKER_01: to other countries like the US,
- 17:23SPEAKER_01: Europe, Japan, China right now, which is doing incredible things in this area.
- 17:30SPEAKER_01: Yeah.
- 17:30SPEAKER_00: Again, my newfound instant expertise,
- 17:33SPEAKER_00: you would not believe how many of
- 17:35SPEAKER_00: the research papers I'm reading are coming right out of Chinese universities.
- 17:38SPEAKER_01: I believe it.
- 17:39SPEAKER_00: Yeah.
- 17:39SPEAKER_00: And well, I guess actually maybe you would.
- 17:41SPEAKER_00: Maybe the audience wouldn't.
- 17:42SPEAKER_00: But my default expectation had been that it would all be coming out of America.
- 17:48SPEAKER_00: And some of it is definitely.
- 17:50SPEAKER_00: But wow, it's a lot of China.
- 17:51SPEAKER_01: It is so impressive.
- 17:53SPEAKER_01: What China has been able to do since 2015.
- 17:55SPEAKER_01: Yeah.
- 17:58SPEAKER_01: Is breathtaking in terms of speed.
- 18:01SPEAKER_01: They have learned,
- 18:02SPEAKER_01: they have adapted,
- 18:03SPEAKER_01: they have changed their regulatory system to make things go more quickly.
- 18:08SPEAKER_01: They have learned from the best of what's going on internationally.
- 18:12SPEAKER_01: They've adopted it and then they have tinkered with it to make it as efficient as possible.
- 18:17SPEAKER_01: And so groups now are able to run clinical trials in China Unbelievably quickly at
- 18:23SPEAKER_01: a very reasonable cost.
- 18:25SPEAKER_01: But what is even more impressive is the level of innovation that is coming out of China.
- 18:31SPEAKER_01: So over the past 10 years,
- 18:33SPEAKER_01: in 2015,
- 18:34SPEAKER_01: we have gone from zero drug products being licensed out of China,
- 18:40SPEAKER_01: or close to, to 30% of licensing deals being signed with pharma.
- 18:46SPEAKER_01: And this was last year, coming from China.
- 18:50SPEAKER_01: A decade.
- 18:51SPEAKER_00: Yeah.
- 18:52SPEAKER_01: It is incredible.
- 18:53SPEAKER_01: And when you hear,
- 18:55SPEAKER_01: you know,
- 18:55SPEAKER_01: the CEOs of the large pharmas like AstraZeneca, they,
- 19:00SPEAKER_01: you know,
- 19:00SPEAKER_01: with the discussions that are taking place in the US right now,
- 19:04SPEAKER_01: where there is some reticence and,
- 19:06SPEAKER_01: you know,
- 19:06SPEAKER_01: the Americans are feeling the heat,
- 19:09SPEAKER_01: you know,
- 19:09SPEAKER_01: and the pressure,
- 19:10SPEAKER_01: right, from this incredible competitor that's coming up and that might eclipse them.
- 19:14SPEAKER_01: And to hear American CEOs say,
- 19:17SPEAKER_01: Please don't get in our way because most of
- 19:20SPEAKER_01: the pharmaceutical companies are facing patent cliffs
- 19:23SPEAKER_01: and there is amazing stuff coming out of China.
- 19:28SPEAKER_01: Amazing stuff.
- 19:29SPEAKER_00: Those big US pharma giants, they're all making money off things.
- 19:32SPEAKER_00: They're going to turn generic in the near future.
- 19:34SPEAKER_01: Yeah.
- 19:35SPEAKER_00: Okay.
- 19:35SPEAKER_00: So I have a question I wanted to ask you about that,
- 19:38SPEAKER_00: but I want to sneak in one more follow-up question first.
- 19:40SPEAKER_00: You talked about,
- 19:42SPEAKER_00: I don't remember the exact term you used this a minute ago,
- 19:43SPEAKER_00: but a 13% fail rate or...
- 19:46SPEAKER_01: 13% success rate at CIHR.
- 19:47SPEAKER_01: Okay, well, that's way worse.
- 19:48SPEAKER_01: Yeah, which is... No, I know.
- 19:50SPEAKER_01: It's really tough being a researcher.
- 19:53SPEAKER_00: And does that mean... What is the 13%?
- 19:56SPEAKER_00: The number of things that go the way the scientist expected?
- 19:58SPEAKER_01: Yes, that actually receive funding from CIHR.
- 20:01SPEAKER_00: Oh, wow.
- 20:01SPEAKER_00: Okay.
- 20:02SPEAKER_01: Yes.
- 20:02SPEAKER_01: So there's so much pressure in health research right now in Canada and limited funds, right?
- 20:08SPEAKER_01: And then when we're talking about...
- 20:10SPEAKER_01: Most of the investments are made in early stage research,
- 20:15SPEAKER_01: and we're very well aware at BioCanRx about You know,
- 20:20SPEAKER_01: what types of investments we invest in cancer immunotherapy development,
- 20:24SPEAKER_01: any kind of cancer immunotherapy.
- 20:26SPEAKER_01: So we collect a lot of information about performance, what the investments look like.
- 20:32SPEAKER_01: And so we know that in our case and in cancer in general,
- 20:36SPEAKER_01: around half a billion,
- 20:38SPEAKER_01: it's not insignificant,
- 20:39SPEAKER_01: half a billion dollars get invested every year in cancer research.
- 20:43SPEAKER_01: The vast majority goes to early stage research,
- 20:47SPEAKER_01: then infrastructure,
- 20:48SPEAKER_01: And there's very little left over to do this translational research piece,
- 20:53SPEAKER_01: which is also very expensive to do.
- 20:56SPEAKER_00: So let's actually zoom in on that then,
- 20:58SPEAKER_00: because I want to make sure I understand what the translational part is.
- 21:01SPEAKER_00: So I'm a Canadian scientist.
- 21:03SPEAKER_00: I'm one of the ones who got lucky.
- 21:04SPEAKER_00: I'm one of the 13% who actually got my proposal funded.
- 21:08SPEAKER_00: And I have turned that money into something successful.
- 21:10SPEAKER_00: It looks really, really good in a lab.
- 21:13SPEAKER_00: Then I have no money to do all the stuff that comes next.
- 21:16SPEAKER_00: Because as you talked about, you have to do the test to validate.
- 21:19SPEAKER_00: You then have to get a clinical trial.
- 21:21SPEAKER_00: Then you need to do probably,
- 21:23SPEAKER_00: I'm assuming thousands of pages of procedural paperwork and compliance.
- 21:28SPEAKER_01: Yes, you do.
- 21:29SPEAKER_00: Who funds any of that?
- 21:31SPEAKER_01: So it's a great question.
- 21:34SPEAKER_01: Almost no one.
- 21:35SPEAKER_01: So the irony or what I see in the ecosystem is
- 21:43SPEAKER_01: We'll develop a product to a certain stage, and we're very interested in the clinical trial.
- 21:50SPEAKER_01: And there are different programs all over across the country from charities,
- 21:55SPEAKER_01: from NGOs,
- 21:57SPEAKER_01: From the federal government,
- 21:58SPEAKER_01: provincial governments that will fund the discovery,
- 22:01SPEAKER_01: that will fund the clinical trial.
- 22:03SPEAKER_01: Nobody is funding the middle, which is going from bench all the way to the bedside.
- 22:10SPEAKER_01: And I have my theories as to why.
- 22:13SPEAKER_01: I just don't think that our systems are set up.
- 22:16SPEAKER_01: And it really links back to the program pressure under which the funders are under.
- 22:23SPEAKER_01: The...
- 22:25SPEAKER_01: Once you get to development, I call it the unsexy part of research because it's development.
- 22:33SPEAKER_01: There's nothing new.
- 22:34SPEAKER_01: You've already had your nature publication.
- 22:37SPEAKER_01: Now you're validating, making sure that the results are good.
- 22:40SPEAKER_01: And if it's in nature, probably it is.
- 22:43SPEAKER_01: But then it's development and there's no student training, right?
- 22:47SPEAKER_01: Because you need expert technicians,
- 22:50SPEAKER_01: research associates to be Working on,
- 22:53SPEAKER_01: you know, putting together this regulatory package.
- 22:56SPEAKER_01: It's also regulatory science.
- 22:58SPEAKER_01: It's very different from what a researcher does day to day to fulfill
- 23:03SPEAKER_01: the requirements of Health Canada.
- 23:05SPEAKER_01: And so different questions get asked and they have to fulfill different obligations.
- 23:10SPEAKER_01: And that in and of itself is an adventure.
- 23:14SPEAKER_01: But that middle part is almost entirely unfunded in Canada.
- 23:19SPEAKER_00: I think we've all seen the movie scene where the insomniac scientist guzzling
- 23:25SPEAKER_00: the energy drinks has that breakthrough moment in the dark lab in the middle of
- 23:28SPEAKER_00: the night.
- 23:28SPEAKER_00: And that's portrayed as the part in the movie, it's like, my God, we did it.
- 23:34SPEAKER_00: The middle third of the movie is not thousands and thousands of hours being put
- 23:39SPEAKER_00: into paperwork in triplicate and in both official languages to get the approval
- 23:44SPEAKER_00: And that's actually where I'm imagining most of these things die.
- 23:47SPEAKER_00: And I had said to you like a minute ago, where does the money come from?
- 23:51SPEAKER_00: And you said almost nowhere.
- 23:52SPEAKER_00: I have a hunch that actually those Canadian researchers,
- 23:56SPEAKER_00: when they go looking for the money, they probably look outside of Canada.
- 24:00SPEAKER_01: Yes, absolutely.
- 24:02SPEAKER_01: And it's a huge part of the reason why we struggle with being able to And
- 24:08SPEAKER_01: to keep our innovations here in the country because other jurisdictions,
- 24:15SPEAKER_01: for example, the US, are much more comfortable with risk.
- 24:20SPEAKER_01: Canadian culture, we are not.
- 24:22SPEAKER_01: And then what happens?
- 24:23SPEAKER_01: Those investments start to come in, especially if there's a good idea.
- 24:26SPEAKER_01: And there are pockets of Canadian investors that are beginning to invest.
- 24:32SPEAKER_01: The desire from those investors is also,
- 24:35SPEAKER_01: especially in Canada, to invest in something that is far more de-risked.
- 24:40SPEAKER_01: So they will be looking for that early stage phase one study in order to say,
- 24:45SPEAKER_01: yeah, we're comfortable with making that kind of investment.
- 24:54SPEAKER_01: Other investors will be far more comfortable with being able to fund that.
- 24:57SPEAKER_01: And I'm not saying that everything is peaches and cream in the US.
- 25:01SPEAKER_01: Speaking to folks, it's also really tough right now in biotech.
- 25:05SPEAKER_01: But there are different programs in the United States that understand this process
- 25:10SPEAKER_01: and the life cycle of drug development.
- 25:13SPEAKER_01: And the most important thing, they're okay with it.
- 25:16SPEAKER_01: It's like we're okay with it.
- 25:19SPEAKER_01: We understand what it takes to get from preclinical all the way to the clinic,
- 25:25SPEAKER_01: and it requires this work.
- 25:27SPEAKER_01: And so we need programs that understand this work and understand that it's necessary
- 25:34SPEAKER_01: in order to get to what I call the cherry on top of the cake,
- 25:38SPEAKER_01: which is the clinical trial.
- 25:40SPEAKER_00: You said a minute ago that you had a hunch,
- 25:42SPEAKER_00: and I hope I'm not getting into trouble when I ask you what the hunch is.
- 25:45SPEAKER_00: Hopefully it's not salacious here.
- 25:47SPEAKER_00: I would guess that the hunch is that the politicians want to put the money into
- 25:52SPEAKER_00: where they get the really cool story of a breakthrough.
- 25:55SPEAKER_00: That is made in Canada.
- 25:56SPEAKER_00: And maybe some Canadian gets a Nobel Prize and the university gets to talk about,
- 26:00SPEAKER_00: man, look, our researchers just crack this thing.
- 26:03SPEAKER_00: And then that gets, as you said, that gets into the journals.
- 26:05SPEAKER_00: That attracts more funding.
- 26:07SPEAKER_00: That attracts more students.
- 26:08SPEAKER_00: It gets a lot of attention.
- 26:09SPEAKER_00: But no one has figured out yet what the advantage is of all that stuff in the middle.
- 26:15SPEAKER_00: And I could be wrong about this,
- 26:17SPEAKER_00: but the reason this is my hunch is because in almost every field
- 26:20SPEAKER_00: of Canadian endeavour,
- 26:22SPEAKER_00: All of the political advantages derived from the announcement.
- 26:26SPEAKER_00: And this is something my colleague Jen and I would talk about.
- 26:28SPEAKER_00: The announcement is the plan.
- 26:30SPEAKER_00: Like, you know, it's like, well, we've got a problem in this country.
- 26:33SPEAKER_00: And then all the politicians get there.
- 26:36SPEAKER_00: They have a lectern with like a bespoke label.
- 26:39SPEAKER_00: It's like more jobs for Canadians or, you know, immunotherapy for Canadians.
- 26:44SPEAKER_00: Right.
- 26:44SPEAKER_00: And they all show up and they talk about we are committing
- 26:46SPEAKER_00: a hundred million dollars They all get their thing and then they clip that endlessly
- 26:52SPEAKER_00: for their brochures and social media and none of them care about the guy who's got
- 26:57SPEAKER_00: to write the 3,000 pages of compliance documents because they got their benefits.
- 27:01SPEAKER_00: Am I wildly off or do you think that's about where the problem is?
- 27:08SPEAKER_00: We've had a few examples in Canada
- 27:11SPEAKER_01: of those kinds of success stories,
- 27:13SPEAKER_01: but they're few and far between.
- 27:15SPEAKER_01: And there are up-and-comers across the country that are worth watching,
- 27:19SPEAKER_01: where I think those types of announcements,
- 27:21SPEAKER_01: and I can guarantee, no, they won't care about how long it's taken.
- 27:29SPEAKER_01: It's a high-risk area of research,
- 27:32SPEAKER_01: because even if you get good results at phase one,
- 27:36SPEAKER_01: even at phase two,
- 27:37SPEAKER_01: we hear and read all the time this drug,
- 27:41SPEAKER_01: pharmaceutical company X,
- 27:43SPEAKER_01: a stock We're stopping this clinical trial because it's failed at phase three.
- 27:47SPEAKER_01: We're talking about hundreds of millions of dollars, right?
- 27:51SPEAKER_01: And these are the numbers, and the timescale is enormous.
- 27:55SPEAKER_01: You're talking about a decade, if not more, of work.
- 27:58SPEAKER_01: So they take time.
- 27:59SPEAKER_01: They don't fit nicely with the electoral cycle, unfortunately, but it's a reality.
- 28:06SPEAKER_01: And so it makes it all the more challenging.
- 28:10SPEAKER_01: You're talking about potential cures for patients.
- 28:15SPEAKER_01: And to be able to provide access to a novel approach to a patient,
- 28:23SPEAKER_01: we on our team have had that opportunity through the,
- 28:26SPEAKER_01: and I don't want to call it opportunity,
- 28:28SPEAKER_01: but we've had that experience of bringing a certain type of therapy here in Canada
- 28:35SPEAKER_01: that previously wasn't available.
- 28:39SPEAKER_01: It's...
- 28:41SPEAKER_01: It's a gift to be able to do that.
- 28:44SPEAKER_00: Maybe this reflects our personalities, but you gave me the cheerful version of it.
- 28:48SPEAKER_00: Let me give you the sad version of it,
- 28:50SPEAKER_00: which is an old family friend of ours been gone now almost 20 years.
- 28:56SPEAKER_00: He passed away from a cancer that was cured two years later.
- 29:00SPEAKER_00: And what a terrible thing for his family to have lived with,
- 29:04SPEAKER_00: because if anything,
- 29:07SPEAKER_00: Anything in that chain of discovery had moved two years quicker.
- 29:10SPEAKER_00: If you had knocked a couple of months off a regulatory approval here, if,
- 29:14SPEAKER_00: you know,
- 29:15SPEAKER_00: look, you can go insane thinking of the what ifs, but like I think about him often.
- 29:22SPEAKER_00: Especially with my own family now having its own cancer battle.
- 29:25SPEAKER_00: I made a point earlier of thinking to myself, we will not be the ones who fall two years short.
- 29:31SPEAKER_00: That's not something I want to spend the rest of my life living with here.
- 29:34SPEAKER_00: So delays matter.
- 29:35SPEAKER_00: Speed matters.
- 29:37SPEAKER_00: And so when we talk about the translational stuff,
- 29:40SPEAKER_00: I do want to talk to you a little bit about the role your organization has.
- 29:43SPEAKER_00: But before I do that, I want to reverse the onus for a second here.
- 29:49SPEAKER_00: You're not with the government,
- 29:50SPEAKER_00: you don't speak for the government, but you speak to the government.
- 29:52SPEAKER_01: Yes.
- 29:54SPEAKER_00: What do they want?
- 29:56SPEAKER_00: To the extent they understand the sector,
- 29:58SPEAKER_00: if you were to go and talk to the guys at Health Canada or PMO or
- 30:02SPEAKER_00: the provincial health ministries, what do they consider winning?
- 30:05SPEAKER_00: What's a victory for them?
- 30:08SPEAKER_00: They're probably not thinking, man, I would love to cure pancreatic cancer.
- 30:11SPEAKER_00: They're probably thinking something more along the lines of,
- 30:14SPEAKER_00: it would be amazing if we had jobs or if we had a really good research facility.
- 30:18SPEAKER_00: How would they define a win?
- 30:21SPEAKER_01: Phenomenal question.
- 30:23SPEAKER_01: So building up Canadian capacity in terms of being able
- 30:28SPEAKER_01: to produce advanced therapeutics, jobs, absolutely become part of it.
- 30:34SPEAKER_01: Very much on,
- 30:36SPEAKER_01: I think,
- 30:36SPEAKER_01: any provincial or the Canadian government's mind is being able
- 30:41SPEAKER_01: to scale our companies here, right?
- 30:45SPEAKER_01: How do we keep them here?
- 30:47SPEAKER_01: What are the levers that we need to think about in order to be able to keep them here?
- 30:52SPEAKER_01: What kind of funding instruments do we need to think of?
- 30:57SPEAKER_01: Ultimately, how are we going to perhaps align procurement in the drug space?
- 31:03SPEAKER_01: And it's highly complex because we don't have one health system.
- 31:06SPEAKER_01: We have many.
- 31:07SPEAKER_01: And how do we align procurement with the
- 31:14SPEAKER_01: Industrial policy in order to support our own life science companies in Canada.
- 31:20SPEAKER_01: That's what they're thinking about.
- 31:22SPEAKER_01: And what we need to understand is there needs to be continuity.
- 31:28SPEAKER_01: There needs to be handoffs between different types of activities
- 31:33SPEAKER_01: and understanding these things take time.
- 31:36SPEAKER_01: We're going to fail.
- 31:38SPEAKER_01: And this is the biggest thing I think that we need to learn how to do in Canada.
- 31:42SPEAKER_01: We need to be able to be okay with failure and accept it, learn, and move on quickly, quickly.
- 31:53SPEAKER_01: I know it's a big ask.
- 31:54SPEAKER_00: Just the idea of...
- 31:58SPEAKER_00: Every once in a while you have a weird moment where someone leaves like some cheese
- 32:01SPEAKER_00: in the lab over the weekend and we end up with penicillin.
- 32:04SPEAKER_00: But like most of the time we have vague notions of something that ought to work in
- 32:09SPEAKER_00: a laboratory model that then later works in a mouse.
- 32:12SPEAKER_00: We test it out on some people and it kind of works.
- 32:14SPEAKER_00: So we try it in a bigger group of people and it still works.
- 32:17SPEAKER_00: And then we try it in a really big group of people and it works.
- 32:19SPEAKER_00: And that becomes a drug that either cures something or even just improves quality of life.
- 32:24SPEAKER_00: And I shouldn't say that like dismissively,
- 32:26SPEAKER_00: but like not everything is a knockout cure,
- 32:28SPEAKER_00: but medications treated that make lives better,
- 32:31SPEAKER_00: reduce suffering, and sometimes actually defeat diseases.
- 32:34SPEAKER_00: The problem is that drug is probably one of 9,000 that was being tried out to go out
- 32:39SPEAKER_00: and defeat that exact issue.
- 32:41SPEAKER_00: And the other 8,999 didn't work or at least didn't work as well.
- 32:47SPEAKER_00: I look at that and I would think to myself, my God, we threw a lot of money at this.
- 32:50SPEAKER_00: And at the end of it,
- 32:51SPEAKER_00: we had a drug or treatment or an immunotherapy that actually saved lives
- 32:55SPEAKER_00: or extended life or relieved suffering.
- 32:58SPEAKER_00: Whereas I absolutely guarantee you, I probably don't need to convince you of this.
- 33:02SPEAKER_00: The Canadian bureaucrat would look at that and they would go,
- 33:04SPEAKER_00: my God, all these failures to only get one drug at the end of it.
- 33:09SPEAKER_00: And the reason,
- 33:11SPEAKER_00: even though I don't know nearly as much about your sector as you do,
- 33:15SPEAKER_00: I don't need to because that's a pan-Canadian reflex.
- 33:18SPEAKER_00: Yes.
- 33:20SPEAKER_00: If I were to put you in a room with people who do software or technology
- 33:25SPEAKER_00: or agricultural products or energy products,
- 33:27SPEAKER_00: and I know this for a fact because I've had versions of this conversation with them,
- 33:31SPEAKER_00: they would say, we do not get rewarded for our success.
- 33:35SPEAKER_00: We get grilled for all of the little incremental failures on the road to that success.
- 33:41SPEAKER_00: And...
- 33:42SPEAKER_00: Sooner or later,
- 33:43SPEAKER_00: some MP is going to stand up in the house and go,
- 33:45SPEAKER_00: why are we funding all these drugs that failed?
- 33:48SPEAKER_00: And they're never going to know.
- 33:48SPEAKER_00: It's because that's what was required to get to the one that worked.
- 33:51SPEAKER_01: Exactly.
- 33:52SPEAKER_01: Yes, absolutely.
- 33:53SPEAKER_01: So well said.
- 33:54SPEAKER_01: Absolutely.
- 33:55SPEAKER_01: I remember once having somebody that we were working with and we're talking about
- 34:01SPEAKER_01: the number of patients that we've treated,
- 34:03SPEAKER_01: the amount of funding that we've been able to get from the government.
- 34:07SPEAKER_01: And I've been really struck because we have treated hundreds of patients,
- 34:11SPEAKER_01: which for an early stage, Clinical trial funder like us is absolutely phenomenal.
- 34:18SPEAKER_01: Understand that a phase one clinical trial typically treats 10 to 20 patients.
- 34:25SPEAKER_01: And we're way past 400, which is a lot.
- 34:28SPEAKER_01: And I was struck by not being able to see or just seeing,
- 34:33SPEAKER_01: you know,
- 34:33SPEAKER_01: you've had so many millions of dollars of research and you've only treated patients.
- 34:38SPEAKER_01: A couple of hundred patients.
- 34:39SPEAKER_01: And that has always stuck with me about the work that we need to do in terms
- 34:45SPEAKER_01: of better communicating that as a country.
- 34:50SPEAKER_01: Do we want to be able to make our own products?
- 34:54SPEAKER_01: Do we want to know and have the capacity to make our own products?
- 34:58SPEAKER_01: Do we want to learn how to develop and adopt new technologies and deliver them
- 35:04SPEAKER_01: in our health care system?
- 35:06SPEAKER_01: This episode is also brought to you by the Forest Products Association of Canada.
- 35:32SPEAKER_00: Budget season in Ottawa is filled with asks for new programs,
- 35:35SPEAKER_00: new tax measures, and new investment.
- 35:37SPEAKER_00: But for Canada's forest products sector,
- 35:40SPEAKER_00: the biggest opportunity for growth doesn't require new spending.
- 35:43SPEAKER_00: It requires smarter rules.
- 35:45SPEAKER_00: Regulatory efficiencies are costing the average Canadian mill
- 35:49SPEAKER_00: an estimated $1 million a year, each.
- 35:52SPEAKER_00: That's money that could be reinvested in workers, communities, and modernization instead.
- 35:58SPEAKER_00: The Forest Sector Transformation Task Force gave Ottawa a clear playbook.
- 36:03SPEAKER_00: As the federal budget takes shape,
- 36:05SPEAKER_00: the fastest way to unlock private investment is to remove the made
- 36:08SPEAKER_00: in Canada barriers standing in the way.
- 36:11SPEAKER_00: Learn more at fpac.ca.
- 36:18SPEAKER_00: We were talking a minute ago about the number of failures on the way to a single success.
- 36:24SPEAKER_00: And you were talking about how Yeah.
- 36:50SPEAKER_00: One of the things,
- 36:51SPEAKER_00: and we've talked a little bit about risk aversion in Canada,
- 36:54SPEAKER_00: and you had hinted at this because you also talked about research
- 36:57SPEAKER_00: and development cycles versus political cycles.
- 37:00SPEAKER_00: And I had said to you a minute ago that there were a lot of other people
- 37:03SPEAKER_00: in different sectors in Canada who would feel your pain,
- 37:06SPEAKER_00: who have absolutely nothing to do with immunotherapies or cancer research or biotech
- 37:11SPEAKER_00: at all,
- 37:11SPEAKER_00: but have lived through the nightmare of the Project that will take 10 years cycling
- 37:18SPEAKER_00: through three different governments.
- 37:20SPEAKER_00: Each one reboots it because they come in and go, we don't understand this.
- 37:24SPEAKER_00: We've put our new minister in.
- 37:25SPEAKER_00: We think it should be going this way here.
- 37:28SPEAKER_00: How the hell do you navigate a 10-year research trial through something
- 37:32SPEAKER_00: that is going to involve probably three elections during that time?
- 37:35SPEAKER_00: Yeah.
- 37:38SPEAKER_00: Maybe a loaded question here,
- 37:39SPEAKER_00: but are governments generally good about not blowing up the research midstream,
- 37:43SPEAKER_00: or do they tend to come in and just go,
- 37:45SPEAKER_00: oh, well, we're new and we're going to cancel everything?
- 37:48SPEAKER_01: It can happen.
- 37:49SPEAKER_01: And we've had...
- 37:52SPEAKER_01: We've had a lot,
- 37:53SPEAKER_01: we've undergone an enormous amount of change and we've had
- 37:55SPEAKER_01: to navigate program cuts coming within three months of shutting down,
- 38:02SPEAKER_01: despite delivering lifesaving treatments to Canadians that were not available
- 38:07SPEAKER_01: in certain provinces.
- 38:10SPEAKER_01: We've done that.
- 38:13SPEAKER_01: And I think the best answer and what resonates the most with the bureaucracy and
- 38:19SPEAKER_01: with politicians is the impact that we've been able to have with respect
- 38:24SPEAKER_01: to actually having an impact on patients and their lives
- 38:28SPEAKER_01: and offering them brand new treatments that they otherwise wouldn't have had access
- 38:32SPEAKER_01: to.
- 38:33SPEAKER_01: That is one.
- 38:34SPEAKER_01: And it's really important to be able to tell that story.
- 38:37SPEAKER_01: And it's data on performance and how effective are we in Canada
- 38:43SPEAKER_01: in taking discoveries and turning them into products?
- 38:46SPEAKER_01: And this is a metric that is...
- 38:49SPEAKER_01: Not examined and being the kind of group that we are, we're very interested in performance.
- 38:56SPEAKER_01: Our whole program is about performance.
- 38:58SPEAKER_01: Our whole program is about turning discoveries into products as efficiently and efficiently.
- 39:04SPEAKER_01: As quickly as possible,
- 39:06SPEAKER_01: using the best that science has to offer to offer brand new products
- 39:11SPEAKER_01: to Canadian patients via clinical trials.
- 39:14SPEAKER_01: So having that kind of data that shows we have a program
- 39:19SPEAKER_01: that connects Different investments that have taken place in Canada,
- 39:23SPEAKER_01: be it infrastructure,
- 39:25SPEAKER_01: be it funding,
- 39:26SPEAKER_01: to capacity building,
- 39:28SPEAKER_01: to being able to create new companies and launch clinical trials in
- 39:34SPEAKER_01: a timely manner is invaluable.
- 39:39SPEAKER_00: I have done my best to keep you away from questions that might get you into trouble,
- 39:42SPEAKER_00: but at a certain point it does become unavoidable.
- 39:45SPEAKER_00: I do have to ask about politics to this extent.
- 39:48SPEAKER_00: We do have a new government and a federal government,
- 39:50SPEAKER_00: and we have a government that is certainly announced a series of new priorities,
- 39:54SPEAKER_00: and I'm going to.
- 39:56SPEAKER_00: We
- 39:59SPEAKER_00: do not want to be as militarily reliant on the United States.
- 40:05SPEAKER_00: We do not want to be as economically reliant on the United States.
- 40:09SPEAKER_00: Just a few days before you and I are recording this,
- 40:12SPEAKER_00: Canada and Europe talking about banking transfers and international payments
- 40:16SPEAKER_00: and cloud software and all of these things.
- 40:21SPEAKER_00: And I, okay, sure.
- 40:23SPEAKER_00: I mean, sounds good.
- 40:24SPEAKER_00: I'm all in with that.
- 40:26SPEAKER_00: It just occurs to me that we will be a country with French banking transfer systems
- 40:34SPEAKER_00: and British weapons and trading our agricultural products with the whole world,
- 40:40SPEAKER_00: keeping ourselves alive with made-in-America medicines.
- 40:44SPEAKER_00: A lot of that original research might actually be Canadian, but then it leaves.
- 40:49SPEAKER_00: And when you were describing to me the...
- 40:52SPEAKER_00: The process by which Canadian tax dollars fund Canadian researchers in Canada
- 40:58SPEAKER_00: who have that breakthrough and then they have to leave the country to do anything
- 41:02SPEAKER_00: with it because there's not a lot of supportive infrastructure there.
- 41:06SPEAKER_00: It occurs to me that if the government of Canada were looking for a good news story
- 41:11SPEAKER_00: and it was like, hey,
- 41:12SPEAKER_00: here's another way we're standing up resilience,
- 41:14SPEAKER_00: it could be keeping Canadians alive.
- 41:18SPEAKER_00: And I actually,
- 41:20SPEAKER_00: for what it's worth,
- 41:21SPEAKER_00: and I will put this in your hands and I will ask you this question in
- 41:23SPEAKER_00: the least loaded way possible, but...
- 41:26SPEAKER_00: I have had some reason to believe that the new government understands that.
- 41:31SPEAKER_00: I don't have a lot of reason to think they have a ton of expertise on this.
- 41:35SPEAKER_00: So I think they might kind of understand it in the sense
- 41:37SPEAKER_00: of we probably should be doing a better job at this.
- 41:41SPEAKER_00: I don't necessarily know they understand how to do that.
- 41:45SPEAKER_00: So for you, the last year and a half, has it been different?
- 41:48SPEAKER_00: Is there a new sheriff in town?
- 41:50SPEAKER_00: Like how has your experience working with the government changed?
- 41:52SPEAKER_00: If it has.
- 41:53SPEAKER_01: So I have to say that I'm really encouraged by the change that I've seen in
- 41:58SPEAKER_01: the past 12 to 18 months.
- 41:59SPEAKER_01: Wow.
- 42:00SPEAKER_01: Okay.
- 42:00SPEAKER_00: Honestly, I'm sorry to interrupt.
- 42:01SPEAKER_00: I didn't expect that answer.
- 42:03SPEAKER_01: I'm very much encouraged in terms of the questions that are being asked by government.
- 42:10SPEAKER_01: The launch,
- 42:10SPEAKER_01: for example,
- 42:11SPEAKER_01: of the Pharmaceutical and Life Science Task Force,
- 42:14SPEAKER_01: we participated in this task force.
- 42:16SPEAKER_01: We sat on this.
- 42:17SPEAKER_01: We unsurprisingly ensured that translational research was represented in
- 42:23SPEAKER_01: the recommendations, clinical trials.
- 42:26SPEAKER_01: Greater support for commercialization because we want to have those success stories
- 42:30SPEAKER_01: that show to Canadians and To really highlight the value
- 42:35SPEAKER_01: of Canadian taxpayers' investments in research,
- 42:38SPEAKER_01: we want to make sure that the best of Canadian science makes it to Canadians.
- 42:44SPEAKER_01: And one way that we can demonstrate that is via the value of clinical trials,
- 42:48SPEAKER_01: and we're doing that right now.
- 42:50SPEAKER_01: So the questions that are being asked with respect to how to,
- 42:54SPEAKER_01: for example,
- 42:55SPEAKER_01: better connect Canadian companies to procurement,
- 42:58SPEAKER_01: What are we doing with respect to regulatory modernization?
- 43:02SPEAKER_01: What can we do for Canadian innovators in terms of better supporting them
- 43:07SPEAKER_01: as they traverse the regulatory process?
- 43:10SPEAKER_01: These are discussions now that we're having with the government.
- 43:14SPEAKER_01: And these were not discussions that we were having before.
- 43:18SPEAKER_01: And so to be able to engage with them on that is, it's a huge opening.
- 43:24SPEAKER_01: I'm going to say confidence in being able to do it by ourselves.
- 43:28SPEAKER_01: And with respect to, you know, your earlier comment on Europe.
- 43:44SPEAKER_01: There is an amazing opportunity for us in Canada.
- 43:48SPEAKER_01: We already collaborate with numerous other countries across the world.
- 43:53SPEAKER_01: We are collaborating with other countries in Europe right now.
- 43:58SPEAKER_01: So we have a collaboration with Denmark, Norway, Sweden, Finland.
- 44:03SPEAKER_01: Lots of interest in the products,
- 44:05SPEAKER_01: and they understand our mission,
- 44:07SPEAKER_01: but lots of interest from other European countries in being able to access the types
- 44:12SPEAKER_01: of products that we're making,
- 44:14SPEAKER_01: Because they want to make them available to their populations as well.
- 44:18SPEAKER_01: So there is a meshing of culture of minds, if I can say.
- 44:25SPEAKER_01: And science can be, and the kind of research that we do can be a conduit to that.
- 44:32SPEAKER_01: And something that Canada,
- 44:33SPEAKER_01: you know,
- 44:34SPEAKER_01: must support,
- 44:35SPEAKER_01: especially in light of the conversations that we're having right now,
- 44:38SPEAKER_01: and the types of relationships that we want to develop with other countries,
- 44:43SPEAKER_01: in particular Europe.
- 44:44SPEAKER_00: The reason your relatively optimistic answer, or you know, I won't even qualify it.
- 44:49SPEAKER_00: The reason your optimistic answer surprised me there is because I talk regularly
- 44:52SPEAKER_00: with people in critical minerals, manufacturing, computational AI.
- 44:58SPEAKER_00: Certainly I talk probably more than it's healthy to guys in the defense sector.
- 45:03SPEAKER_00: And what I've largely been hearing from them is, yeah, they're starting to take us seriously.
- 45:08SPEAKER_00: Like you gave me the most enthusiastic answer I've heard so far.
- 45:12SPEAKER_00: Which is actually encouraging because,
- 45:14SPEAKER_00: you know, everybody loves remembering the pandemic, what fun that was.
- 45:17SPEAKER_00: But I remember the incredibly angry op-eds of,
- 45:22SPEAKER_00: why does Canada not have vaccine production capabilities?
- 45:25SPEAKER_00: I just remember at the time, like banging my head.
- 45:27SPEAKER_00: I had my desk going because of decades of predictable policy and funding choices
- 45:32SPEAKER_00: that led for it not to be economical for us to have these things there.
- 45:36SPEAKER_00: Right.
- 45:36SPEAKER_00: So then we spent, oh,
- 45:37SPEAKER_00: God only knows how much money to stand up these facilities in a crash
- 45:42SPEAKER_00: and crash programs.
- 45:43SPEAKER_00: And then we didn't have products for them to build.
- 45:44SPEAKER_00: Right.
- 45:45SPEAKER_00: So like one of the things I know that I've talked about with your team here is the idea of.
- 45:49SPEAKER_00: If we were better at generating this stuff in Canada,
- 45:52SPEAKER_00: there would be more of a rationale to have economically viable,
- 45:57SPEAKER_00: self-funded,
- 45:57SPEAKER_00: sustained production capabilities to go out the next time something bad happens
- 46:03SPEAKER_00: where we could surge domestically our own high-tech response to it without needing
- 46:08SPEAKER_00: to beg supply from our allies.
- 46:10SPEAKER_00: And I guess, hey,
- 46:10SPEAKER_00: credit where it's due to the former government,
- 46:14SPEAKER_00: Canada was relatively near to the front of The Line.
- 46:17SPEAKER_00: If it happens again, I'd rather just be there by default.
- 46:20SPEAKER_01: I couldn't agree more.
- 46:22SPEAKER_01: And the points that you're making with respect to being able to support,
- 46:26SPEAKER_01: we've made a lot of investments in capacity building.
- 46:30SPEAKER_01: You're right.
- 46:32SPEAKER_01: Those facilities are looking for products to be able to make,
- 46:36SPEAKER_01: and we have to find those products.
- 46:39SPEAKER_01: And this is where having programs that are focused on drug development guarantee
- 46:44SPEAKER_01: the utilization.
- 46:45SPEAKER_01: In the program that we run,
- 46:47SPEAKER_01: we don't let,
- 46:49SPEAKER_01: unless there's a very specific reason to,
- 46:51SPEAKER_01: we don't let the projects go offshore in order to access manufacturing for
- 46:58SPEAKER_01: a certain kind of product.
- 46:59SPEAKER_01: We expect that they're going to be using the facilities here,
- 47:03SPEAKER_01: and there's a number of reasons for that.
- 47:06SPEAKER_01: There's capacity.
- 47:08SPEAKER_01: Two, we want to spend the money in Canada.
- 47:11SPEAKER_01: And it builds up capacity in those different manufacturing facilities that we work with.
- 47:19SPEAKER_01: So all of these things are critically important to have.
- 47:22SPEAKER_01: And I sound positive.
- 47:25SPEAKER_01: Talk to me after the budget.
- 47:27SPEAKER_01: There's supposed to be a response to the pharmaceutical and life science task force.
- 47:33SPEAKER_01: The report is out.
- 47:35SPEAKER_01: The government had,
- 47:38SPEAKER_01: you know,
- 47:38SPEAKER_01: the courage to strike this task force and to ask those questions
- 47:43SPEAKER_01: and assemble those people to discuss what's working, what's not working.
- 47:47SPEAKER_01: I'm very well aware that there have been But right now, today, you catch me on a hopeful note.
- 48:17SPEAKER_00: I don't get to do that often.
- 48:18SPEAKER_00: If you're on a hopeful note today, I'm going to run with that.
- 48:21SPEAKER_00: I have three more questions for you,
- 48:22SPEAKER_00: and one of them is very simple, so I'll save that one to the end.
- 48:25SPEAKER_00: But when we talk about the increasing federal desire,
- 48:30SPEAKER_00: apparently,
- 48:30SPEAKER_00: we'll go with the optimistic take,
- 48:31SPEAKER_00: that the feds get it and they want to make a difference with it.
- 48:36SPEAKER_00: Some of the industries that I've been talking to and talking about,
- 48:40SPEAKER_00: they're looking at if the feds showed up with the money truck today,
- 48:44SPEAKER_00: They would not be able to do much for a decade.
- 48:46SPEAKER_00: It's just that there are long lead times for facilities,
- 48:50SPEAKER_00: technology, permits, approvals, and the feds say they want to fix that.
- 48:55SPEAKER_00: How rapidly could your sector expand?
- 48:57SPEAKER_00: Like, what is the bottleneck there?
- 48:59SPEAKER_00: If money stopped being a problem, what happens tomorrow?
- 49:03SPEAKER_01: Oh, we could mobilize instantaneously.
- 49:06SPEAKER_01: So, you know,
- 49:08SPEAKER_01: and I say this based on very recent experience for,
- 49:13SPEAKER_01: so we run a competitive process in order to assess,
- 49:18SPEAKER_01: right, these different projects that are coming to us.
- 49:21SPEAKER_01: I remember when I first started at BioCanRx,
- 49:25SPEAKER_01: of course,
- 49:26SPEAKER_01: taking a look at the intake of different projects and really asking myself
- 49:30SPEAKER_01: the question, is this the depth of the well in Canada?
- 49:35SPEAKER_01: And are there other developers,
- 49:38SPEAKER_01: other researchers that are working on new different types of products?
- 49:42SPEAKER_01: I can honestly say in this past competitive process we have limited funding.
- 49:49SPEAKER_01: We've received, compared to that other time, a tenfold increase in the number of applications.
- 49:57SPEAKER_01: Unbelievably competitive to show that if we provide Canadian companies
- 50:02SPEAKER_01: and Canadian researchers With the programs and we set the expectations
- 50:06SPEAKER_01: that our goal is to increase the number of clinical trials to be able
- 50:10SPEAKER_01: to provide novel approaches to treating cancer in Canada to patients here,
- 50:16SPEAKER_01: they respond and they deliver.
- 50:18SPEAKER_01: And so, you know, I could mobilize that money in the next second.
- 50:28SPEAKER_00: This episode is also brought to you by Cameco.
- 50:32SPEAKER_00: Building Canada's energy future means creating jobs for Canadian workers.
- 50:36SPEAKER_00: That's why the AP1000 reactor is the right choice for Canada.
- 50:40SPEAKER_00: It is already operating and ready to deliver the power we need.
- 50:45SPEAKER_00: Choosing the AP1000 means a reactor built by Canadians,
- 50:49SPEAKER_00: creating skilled jobs in construction,
- 50:51SPEAKER_00: fabrication,
- 50:51SPEAKER_00: and the trades, while keeping more investment and economic benefits here at home.
- 50:56SPEAKER_00: If we are serious about creating Canadian jobs and strengthening our economy,
- 51:00SPEAKER_00: the choice is clear.
- 51:02SPEAKER_00: To learn more, visit ap1000.cameco.com.
- 51:10SPEAKER_00: When we talk about the money being available and what it would surge to here,
- 51:14SPEAKER_00: there is one other part of it, which is I would say government will.
- 51:19SPEAKER_00: And this is not disconnected from the money.
- 51:24SPEAKER_00: One of the issues that I know that my friends in the defense sector are running
- 51:27SPEAKER_00: into is that there is suddenly money available,
- 51:31SPEAKER_00: but the regulatory environment is so slow that with all the money in the world,
- 51:36SPEAKER_00: they can't spend it.
- 51:37SPEAKER_00: And then they run into other issues like, okay,
- 51:39SPEAKER_00: finally,
- 51:40SPEAKER_00: I got the permits, but there is no one in the country who knows how to build this.
- 51:44SPEAKER_00: So I got to go grab a bunch of kids at a college and teach them to do it.
- 51:48SPEAKER_00: What are your similar constraints?
- 51:50SPEAKER_00: So just in a perfect world, we'll wave our magic wand and we'll fix your money problem.
- 51:56SPEAKER_00: What's your next challenge?
- 51:57SPEAKER_00: I mean, I imagine that would be a nice problem for you to have if the money problem was solved.
- 52:02SPEAKER_00: If we wanted to turn Canada into a giant in biotech and money was no longer
- 52:07SPEAKER_00: an issue, what's your next problem?
- 52:15SPEAKER_01: Interestingly,
- 52:16SPEAKER_01: we had a full day at Health Canada yesterday to talk
- 52:20SPEAKER_01: about closed system manufacturing.
- 52:23SPEAKER_01: It's a piece of equipment that we use to manufacture some of our products.
- 52:28SPEAKER_01: Ways to streamline and improve and just to have better connectivity and interchange
- 52:33SPEAKER_01: with the regulator.
- 52:34SPEAKER_01: So I think that's missing from the Canadian landscape relative to other jurisdictions.
- 52:41SPEAKER_01: I would say for getting to a clinical trial,
- 52:45SPEAKER_01: we work with our researchers to make sure that they're ready to The timelines for
- 52:51SPEAKER_01: that have been increasing.
- 52:53SPEAKER_01: So right now,
- 52:53SPEAKER_01: what I've heard yesterday from some of the project teams is that
- 52:56SPEAKER_01: the lead time is six months to get before the regulator.
- 52:58SPEAKER_01: Yeah.
- 53:17SPEAKER_01: Where it gets more challenging is when you're advancing and going beyond a clinical trial.
- 53:25SPEAKER_01: So I have an example to share with you.
- 53:27SPEAKER_01: We do have a product that we're working on that is quite advanced.
- 53:33SPEAKER_01: We've treated 100 patients, which for an advanced therapeutic is a lot.
- 53:39SPEAKER_01: Market approval for these types of products because they work so well and it's a CAR-T product.
- 53:45SPEAKER_01: Typically,
- 53:46SPEAKER_01: you look at what industry's been able to do,
- 53:48SPEAKER_01: and it's 50 to 75 patients, and they get conditional approvals.
- 53:52SPEAKER_01: They have to collect more data, but they're actually able to sell the product in a jurisdiction.
- 53:57SPEAKER_01: So having 100 patients is highly significant.
- 54:01SPEAKER_01: We wanted to have a discussion with our regulator about our data set,
- 54:06SPEAKER_01: about the data that we had collected for all of these almost 100 patients.
- 54:12SPEAKER_01: We sent a message to Health Canada asking what is available in the United States,
- 54:18SPEAKER_01: which is called an end of phase meeting.
- 54:21SPEAKER_01: And it's an opportunity to meet with a regulator to have that discussion about
- 54:25SPEAKER_01: the data that you've collected so that as a developer,
- 54:28SPEAKER_01: you can make the next decision.
- 54:31SPEAKER_01: Maybe you have to continue recruiting patients.
- 54:34SPEAKER_01: Maybe you need to narrow your indication, but you need to have that discussion.
- 54:38SPEAKER_01: We sent the message and request to Health Canada in March,
- 54:43SPEAKER_01: and it took them three months to To get back to us,
- 54:47SPEAKER_01: we received a three-sentence email apologizing for the delay.
- 54:52SPEAKER_01: So that was the first sentence.
- 54:54SPEAKER_01: The second sentence was no to your request.
- 54:58SPEAKER_01: And the third sentence was you're going to have to file a pre-new drug submission.
- 55:03SPEAKER_01: And a pre-new drug submission is what the large biotechs, the large pharma have to file.
- 55:11SPEAKER_01: We're a small not-for-profit, but we really wanted to have our conversation with our regulator.
- 55:20SPEAKER_01: Our clinicians and scientists really needed to interface with our regulator.
- 55:25SPEAKER_01: So we bit the bullet.
- 55:27SPEAKER_01: And, you know,
- 55:28SPEAKER_01: members of my team worked day and night for months with the clinicians,
- 55:32SPEAKER_01: with the scientists to put together the package to send to Health Canada and
- 55:38SPEAKER_01: to make this request for this meeting to have this conversation.
- 55:42SPEAKER_01: Between the time that we made the request in March to
- 55:46SPEAKER_01: when we finally had our meeting with Health Canada, it was in December.
- 55:50SPEAKER_01: I remember the date.
- 55:51SPEAKER_01: It was December 9th.
- 55:53SPEAKER_01: That's a long time.
- 55:56SPEAKER_01: We as a not-for-profit that is currently funded under the federal government,
- 56:00SPEAKER_01: we obtain our funding in five-year increments.
- 56:05SPEAKER_01: I call it, we're on a timer.
- 56:08SPEAKER_01: Imagine a small company, right,
- 56:10SPEAKER_01: which is drawing down on its funds,
- 56:13SPEAKER_01: having to wait to have that engagement with a regulator.
- 56:17SPEAKER_01: Other jurisdictions have shown us that there are ways to...
- 56:22SPEAKER_01: To provide this kind of service so that an innovator can interact with a regulator
- 56:29SPEAKER_01: and get information and have that interaction.
- 56:32SPEAKER_01: We don't have those mechanisms in Canada that are less formal than a pre-new drug submission.
- 56:41SPEAKER_01: And I think it speaks volumes about...
- 56:45SPEAKER_01: The maturity of our life science sector in Canada,
- 56:49SPEAKER_01: we have so few people that decide to stay here and develop their products
- 56:55SPEAKER_01: that there's not pressure on the system to get the system to innovate
- 57:00SPEAKER_01: to meet our innovators where they are.
- 57:04SPEAKER_01: Whereas you do see this kind of regulatory innovation in the US.
- 57:09SPEAKER_01: They've been doing these types of meetings for years and in Europe.
- 57:15SPEAKER_01: We don't have that.
- 57:16SPEAKER_01: And so I don't blame the regulator.
- 57:19SPEAKER_01: Another pathway does not exist to have that meeting.
- 57:23SPEAKER_01: And so part of our engagement and what we actually heard yesterday during
- 57:29SPEAKER_01: the regulatory meeting where we brought people from all over the country,
- 57:33SPEAKER_01: we had participants from Europe as well,
- 57:36SPEAKER_01: We really need to think about what those touch points look like.
- 57:40SPEAKER_01: So I know it's a long answer to your question, but it's convoluted, it's complex.
- 57:46SPEAKER_01: And right now,
- 57:48SPEAKER_01: our regulatory system and the way that our regulator interacts with companies,
- 57:54SPEAKER_01: different groups,
- 57:56SPEAKER_01: Pathways are limited and it's really geared to large companies, right?
- 58:02SPEAKER_01: It's about reducing.
- 58:04SPEAKER_01: And it's really important because we were talking at the very beginning
- 58:08SPEAKER_01: about long approval times and reimbursement and anything that we can do to reduce
- 58:12SPEAKER_01: that time is critically important.
- 58:15SPEAKER_01: 93% of Canada's drugs come from outside the country.
- 58:20SPEAKER_01: And so it's important to have mechanisms to be able to support those applications
- 58:25SPEAKER_01: that are coming in.
- 58:27SPEAKER_01: But my question is always, what are we doing for the Canadian innovator?
- 58:33SPEAKER_01: And if we decide that this is a capability that we,
- 58:38SPEAKER_01: as a sovereign nation,
- 58:40SPEAKER_01: wish to hold,
- 58:40SPEAKER_01: wish to have,
- 58:42SPEAKER_01: we need to think about these things and have mechanisms so that it can be enabled.
- 58:47SPEAKER_00: I'm afraid the answer to my next question is going to be depressing.
- 58:51SPEAKER_00: If we had a pathway that was similar to what the United States or some of
- 58:55SPEAKER_00: the European countries had, what does that timeline look like?
- 58:58SPEAKER_00: So you were six months after you got your no until you were able to actually finish the process.
- 59:04SPEAKER_00: What would that have taken you in the United States if we had a version of their pathway?
- 59:08SPEAKER_01: It's a great question.
- 59:10SPEAKER_01: I'm not certain,
- 59:11SPEAKER_01: actually,
- 59:12SPEAKER_01: but I think it would have been much shorter because there would have been a pathway.
- 59:17SPEAKER_01: So I know that in Europe,
- 59:18SPEAKER_01: there are a number of pilots that are being run where you are assigned an individual
- 59:24SPEAKER_01: and you get to interface.
- 59:26SPEAKER_01: And we had this great experience speaking to a not-for-profit from Italy
- 59:31SPEAKER_01: that has done unbelievable things.
- 59:33SPEAKER_01: They have commercialized and gotten approval in Europe.
- 59:36SPEAKER_01: And so I can't speak to the timelines,
- 59:38SPEAKER_01: but I do know that they had a direct point of contact within the regulator.
- 1:00:03SPEAKER_01: And then they would assemble the right teams in order to get their questions answered.
- 1:00:10SPEAKER_00: It's not only the nine months you guys spent on that.
- 1:00:14SPEAKER_00: It's the three months you spent waiting for the no to be told to go do the other thing.
- 1:00:21SPEAKER_00: And I mentioned to you that that family friend of ours
- 1:00:24SPEAKER_00: whose cancer was cured two years after he died.
- 1:00:29SPEAKER_00: Eight of those increments in a row...
- 1:00:32SPEAKER_00: That's three months times eight.
- 1:00:33SPEAKER_00: That's how you get to the two years.
- 1:00:36SPEAKER_00: You here, you've mentioned you're not for profit doing this.
- 1:00:39SPEAKER_00: There's what, a dozen of you here?
- 1:00:41SPEAKER_01: Yes.
- 1:00:42SPEAKER_00: And a dozen people are attempting to bridge the gap between 41 million Canadians
- 1:00:48SPEAKER_00: who are eventually going to need some kind of life-saving care or another
- 1:00:52SPEAKER_00: and hundreds of millions of dollars of research that could be generating the thing
- 1:00:57SPEAKER_00: that could save their lives.
- 1:00:59SPEAKER_00: And the missing middle in this country is being held together by you and 11 other people.
- 1:01:05SPEAKER_01: Yeah, and cancer immunotherapy,
- 1:01:06SPEAKER_01: yes, we...
- 1:01:08SPEAKER_00: Oh, no, of course, there'd be versions of you across the country, right?
- 1:01:12SPEAKER_01: Yes, it's...
- 1:01:13SPEAKER_01: I...
- 1:01:16SPEAKER_01: We're honored to have been selected to deliver on this mission.
- 1:01:21SPEAKER_01: We truly, truly are.
- 1:01:22SPEAKER_01: And it's something that we take, as you can imagine, very seriously.
- 1:01:29SPEAKER_01: Part of our job is also telling the story of data,
- 1:01:35SPEAKER_01: of performance,
- 1:01:37SPEAKER_01: and reminding people Gently,
- 1:01:40SPEAKER_01: sometimes not so gently,
- 1:01:42SPEAKER_01: that we can do better and that people in Canada deserve better with respect to
- 1:01:48SPEAKER_01: the performance of the health research ecosystem.
- 1:01:51SPEAKER_01: They really do.
- 1:01:53SPEAKER_00: My last question for you,
- 1:01:55SPEAKER_00: and I'll yield the floor to you on this one,
- 1:01:57SPEAKER_00: is I told you at the very beginning,
- 1:01:59SPEAKER_00: I'm operating at the limits of my knowledge,
- 1:02:01SPEAKER_00: and I've had to learn more about cancer and cancer therapies of all kinds in
- 1:02:06SPEAKER_00: the last 10 months than I ever wanted to.
- 1:02:11SPEAKER_00: The amount of information I've crammed into my brain I think has displaced like most
- 1:02:15SPEAKER_00: of my childhood memories.
- 1:02:16SPEAKER_00: I'm like, what house did I grow up in?
- 1:02:18SPEAKER_00: This is gone.
- 1:02:19SPEAKER_00: But what didn't I ask?
- 1:02:24SPEAKER_00: Because I feel as though there's a...
- 1:02:27SPEAKER_00: I tell this story sometimes, Steph,
- 1:02:29SPEAKER_00: and I'll use salty languages for a second,
- 1:02:32SPEAKER_00: but an old friend of mine was a hand-to-hand combat instructor in the Armed Forces.
- 1:02:36SPEAKER_00: And the advice he would give to every graduating class was,
- 1:02:41SPEAKER_00: congratulations,
- 1:02:41SPEAKER_00: you now know just enough to go out there and get your ass kicked by someone
- 1:02:44SPEAKER_00: who knows a little bit more than you.
- 1:02:46SPEAKER_00: And I always think about that, because I know infinitely more than I did a year ago.
- 1:02:51SPEAKER_00: I probably know about 1% of what you know.
- 1:02:54SPEAKER_00: What do I not understand that people should understand?
- 1:02:57SPEAKER_00: Because I look at people today,
- 1:02:59SPEAKER_00: and I've met some of these people,
- 1:03:01SPEAKER_00: Stephanie, they're alive because the scientific breakthrough arrived just in time.
- 1:03:05SPEAKER_00: And I have family friends who have been without a husband and a father and never got
- 1:03:10SPEAKER_00: to meet his grandkids, right,
- 1:03:12SPEAKER_00: for almost 20 years now because the scientific development didn't arrive in time.
- 1:03:17SPEAKER_00: What do I not know that I should know and what should the audience know?
- 1:03:23SPEAKER_01: That these things take time to develop.
- 1:03:30SPEAKER_01: I would like Canadians,
- 1:03:32SPEAKER_01: and people have asked me,
- 1:03:34SPEAKER_01: of course,
- 1:03:35SPEAKER_01: I'm involved in a number of different working groups and lots of these discussions
- 1:03:39SPEAKER_01: about the health research ecosystem.
- 1:03:43SPEAKER_01: What I want people to know,
- 1:03:44SPEAKER_01: or what I would like people to think,
- 1:03:46SPEAKER_01: and maybe this is pushing it too far, I would like Canadian patients to expect...
- 1:03:54SPEAKER_01: That if they exhaust the standard of care that can be provided to them
- 1:04:01SPEAKER_01: in this country,
- 1:04:02SPEAKER_01: that they expect that a clinical trial will be offered to them and
- 1:04:08SPEAKER_01: that they will have access to a novel approach to treating their cancer
- 1:04:13SPEAKER_01: or treating whatever disease has brought them to a hospital.
- 1:04:18SPEAKER_01: If we can get to that stage of thinking about In the Canadian population,
- 1:04:25SPEAKER_01: imagine what our health research ecosystem would look like.
- 1:04:28SPEAKER_01: Imagine what it would mean for research.
- 1:04:30SPEAKER_01: It would mean we have been able to demonstrate results and we've obtained the buy-in
- 1:04:35SPEAKER_01: of politicians.
- 1:04:36SPEAKER_01: We've obtained the buy-in of the bureaucracy
- 1:04:40SPEAKER_01: and we're really valuing this health research enterprise that we have in Canada.
- 1:04:45SPEAKER_01: If the patient at the end of The Line is going into a hospital and expecting that
- 1:04:50SPEAKER_01: the research will be there for them.
- 1:04:53SPEAKER_00: Stephanie, thank you so much.
- 1:04:55SPEAKER_00: I also want that for Canadians.
- 1:04:57SPEAKER_00: So I wish you nothing but success on that, but thank you for the time.
- 1:05:00SPEAKER_00: Thank you for hosting me here at your offices.
- 1:05:02SPEAKER_00: I really appreciate it.
- 1:05:03SPEAKER_01: Thank you.
- 1:05:04SPEAKER_01: Thank you so much.
- 1:05:05SPEAKER_01: Thank you.
- 1:05:09SPEAKER_00: Once more, folks,
- 1:05:10SPEAKER_00: that was Stephanie Michaud joining me from the BioCanRx headquarters in Ottawa,
- 1:05:15SPEAKER_00: where I traveled to do this interview.
- 1:05:17SPEAKER_00: Sorry, Ottawa friends.
- 1:05:18SPEAKER_00: I didn't have time to visit.
- 1:05:21SPEAKER_00: All the disclosures I feel needed to be made, folks,
- 1:05:23SPEAKER_00: were made at the outset,
- 1:05:24SPEAKER_00: but I do want to thank you for the opportunity to present this episode.
- 1:05:26SPEAKER_00: Obviously, very, very close to my heart for the reasons I think all of you understand.
- 1:05:32SPEAKER_00: Check us out at our main page, www.readtheline.ca.
- 1:05:36SPEAKER_00: Like and subscribe.
- 1:05:36SPEAKER_00: We'll be back with another episode of The Line Podcast on Friday.
- 1:05:40SPEAKER_00: Take good care.
- 1:05:41[music]